21 CFR 250.105
§ 250.105 Gelsemium-containing preparations regarded as prescription drugs.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 250.105, § 250.105 Gelsemium-containing preparations regarded as prescription drugs, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/86158
- Permanent ID
ys:prov:86158@1- SHA-256
9c718a3e5d9ccb13e0537b16ddd98ff7d4ba00c05ddecbced4fe43447b7f5f2d
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
It is the consensus of informed medical opinion that the margin of safety between the therapeutic and toxic concentration of gelsemium is narrow and it is difficult to predict the point at which the dose will be toxic. Very small doses may cause toxic symptoms. It is therefore the view of the Food and Drug Administration that gelsemium is not a proper ingredient in any product that is to be sold without prescription. Accordingly, any drug containing gelsemium will be regarded as misbranded under section 503(b)(4) of the Federal Food, Drug, and Cosmetic Act if its label fails to bear in a prominent and conspicuous fashion the statement “Rx only.”
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.